Clinical Report: Alzheimer Biomarkers Higher in Women
Overview
A cross-sectional study reveals that women aged 60-69 exhibit higher Alzheimer pathology, specifically increased amyloid and tau burdens, compared to men. Despite this, women also demonstrate greater structural brain resilience, indicating a complex relationship between sex and Alzheimer's disease pathology.
Background
Understanding sex differences in Alzheimer's disease is crucial as it may influence diagnosis, treatment, and patient outcomes. This study highlights the need for tailored approaches in managing Alzheimer's, particularly considering the unique biomarker profiles observed in women. The findings underscore the importance of further research into how sex, race, and ethnicity intersect with Alzheimer's pathology.
Data Highlights
| Measure | Women | Men |
|---|---|---|
| Amyloid Burden | Higher | Lower |
| Tau Burden (Braak III-IV) | Higher | Lower |
| Tau Burden (Braak V-VI) | Higher | Lower |
| Cortical Thickness | Greater | Lower |
| White Matter Hyperintensity | Lower | Higher |
Key Findings
- Women aged 60-69 show higher global amyloid burden than men.
- Women exhibit greater tau burden in Braak stages III-IV and V-VI compared to men.
- Women have greater Alzheimer disease signature cortical thickness than men.
- Lower white matter hyperintensity burden is observed in women compared to men.
- Sex differences in tau burden are more pronounced among apolipoprotein E epsilon 4 carriers.
Clinical Implications
Clinicians should consider sex-specific differences in Alzheimer biomarkers when assessing patients. The findings suggest that women, particularly those with apolipoprotein E epsilon 4 status, may require closer monitoring for Alzheimer pathology. Tailoring diagnostic and therapeutic strategies based on these differences could enhance patient care.
Conclusion
This study emphasizes the complexity of Alzheimer's disease pathology in women, revealing both increased risk factors and structural resilience. Further research is necessary to clarify the implications of these findings for clinical practice.
References
- Akinci M, et al., JAMA Network Open, 2026 -- Sex Differences in Alzheimer Disease Imaging Biomarkers in a Diverse, Community-Based Cohort
- Gonzales M, et al., Alzheimer’s & Dementia, 2026 -- Alzheimer’s Risk in Middle Age
- Wang Y, et al., Brain, 2026 -- Correction to: Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females
- Conexiant, 2026 -- A Two-Biomarker Signal for Alzheimer’s Disease
- Alzheimer’s Association, 2025 -- Updated Appropriate Use Criteria for Amyloid and Tau PET
- Retinal Physician — Retinal Biomarkers for Alzheimer Disease
- Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup - PMC
- Sex Differences in Alzheimer Disease Imaging Biomarkers in a Diverse, Community-Based Cohort | Geriatrics | JAMA Network Open | JAMA Network
- FDA approves treatment for adults with Alzheimer’s disease | FDA
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
